TherapeuticsMD Inc. (NYSE MKT:TXMD), an innovative women’s healthcare
company, today announced that the U.S. Patent and Trademark Office has
issued two new patents related to the company’s proprietary SYMBODA™
technology platform. The new patents are U.S. patent No. 8,846,648,
related to methods of treating menopause symptoms with the company’s
combination bio-identical estradiol and bio-identical progesterone
technology, and U.S. patent No. 8,846,649, related to the company’s
hormone formulation compositions.
“With these two new issued patents, we have strengthened the patent
portfolio for our technology platform and the important new drug
candidates that it enables,” said TherapeuticsMD CEO Robert G. Finizio.
“These patents directly support our late-stage pipeline of
investigational bio-identical hormone therapy products and could help
enable a new wave of earlier-stage product candidates to meet women’s
needs.”
About TherapeuticsMD Inc.
TherapeuticsMD Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women.
TherapeuticsMD is developing advanced hormone therapy pharmaceutical
products based on novel technologies that enable delivery of
bio-identical hormones through a variety of dosage forms and
administration routes. The company also manufactures and distributes
branded and generic prescription prenatal vitamins, as well as
over-the-counter vitamins and cosmetics, under the vitaMedMD®
and BocaGreenMD® brands. More information is available at the
following websites: www.therapeuticsmd.com,
www.vitamedmd.com,
www.vitamedmdrx.com
and www.bocagreenmd.com.
This press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements may include, but are not limited to, statements relating to
TherapeuticsMD’s objectives, plans and strategies as well as statements,
other than historical facts, that address activities, events or
developments that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are often
characterized by terminology such as “believes,” “hopes,” “may,”
“anticipates,” “should,” “intends,” “plans,” “will,” “expects,”
“estimates,” “projects,” “positioned,” “strategy” and similar
expressions and are based on assumptions and assessments made in light
of management’s experience and perception of historical trends, current
conditions, expected future developments and other factors believed to
be appropriate. Forward-looking statements in this press release are
made as of the date of this press release, and the company undertakes no
duty to update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking statements
are described in the sections titled “Risk Factors” in the company’s
filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as
well as reports on Form 8-K, and include the following: the company’s
ability to maintain or increase sales of its products; its ability to
develop and commercialize its hormone therapy drug candidates and obtain
additional financing necessary therefor; the length, cost and uncertain
results of its clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; its reliance on third parties to
conduct its clinical trials, research and development and manufacturing;
the availability of reimbursement from government authorities and health
insurance companies for the company’s products; the impact of product
liability lawsuits; and the influence of extensive and costly government
regulation.
PDF copies of the company’s historical press releases and financial
tables can be viewed and downloaded at our website: www.therapeuticsmd.com/pressreleases.aspx.
Copyright Business Wire 2014